Topiramate serum concentration-to-dose ratio: Influence of age and concomitant antiepileptic drugs and monitoring implications

Therapeutic Drug Monitoring

Volumn 26, Issue 3, 2004, Pages 251-257

  Adín, Javier ^a   Cruz Gomez M ^a   Blanco, Yolanda ^a   Herranz, José L ^a   Armijo, Juan A ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Antiepileptic drugs; Concentration to dose ratio; Epilepsy; Pharmacokinetic interactions; Therapeutic drug monitoring; Topiramate

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ADOLESCENT; ADULT; AGE; AGED; ANALYSIS OF VARIANCE; ARTICLE; CHILD; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MONITORING; EPILEPSY; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEADY STATE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FRUCTOSE; HUMANS; INFANT; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 2542531483     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200406000-00005     Document Type: Article

References (33)

1. Glauser TA. Topiramate. Epilepsia. 1999;40(suppl 5):71-80.
2. Reife R, Pledger G, Wu SC. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia. 2000;41(suppl 1):66-71.
3. Shank RP, Gardocki JF, Streeter AJ, et al. An overview of the preclinical aspects of topiramate pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41(suppl 1):3-9.
4. Garnett WR. Clinical pharmacology of topiramate: a review. Epilepsia. 2000;41(suppl 1):61-65.
5. Gisclon LG, Curtin CR, Kramer LD. The steady-state (SS) pharmacokinetics (PK) of phenytoin (Dilantin®) and topiramate (Topamax®) in epileptic patients on monotherapy, and during combination therapy. Epilepsia. 1994;35(suppl 8):54.
6. Sachdeo RC, Sachdeo SK, Levy RH, et al. Topiramate and phenytoin pharmacokinetic during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia. 2002;43:691-696.
7. Sachdeo RC, Sachdeo SK, Walker SA, et al. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia. 1996;37:774-780.
8. Rosenfeld WE, Liao S, Kramer LD, et al. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia. 1997;38:324-333.
9. May TW, Rambeck B, Jurgens U. Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication. Ther Drug Monit. 2002;24:366-374.
10. Glauser TA, Miles MV, Tang P, et al. Topiramate pharmacokinetics in infants. Epilepsia. 1999;40:788-791.
11. Rosenfeld WE, Doose DR, Walker SA, et al. A study of topiramate pharmacokinetics and tolerability in children with epilepsy. Pediatr Neurol. 1999;20:339-344.
12. Christensen J, Poulsen JH, Dam M. Effects of age, gender, body weight and dosing profile on steady state trough concentrations of topiramate. Epilepsia. 1999;430(suppl 7):105.
13. Doose DR, Larson KL, Natarajan J, et al. Comparative single-dose pharmacokinetics of topiramate in elderly versus young men and women. Epilepsia. 1998;39(suppl 6):56.
14. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet. 2000;38:191-204.
15. Tomson T, Johannessen SI. Therapeutic monitoring of the new antiepileptic drugs. Eur J Clin Pharmacol. 2000;55:697-705.
16. Cohen AF, Land GS, Breimer DD, et al. Lamotrigine a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther. 1987;42:535-541.
17. Herranz JL, Arteaga R, Armijo JA. Three-year efficacy and tolerability of add-on lamotrigine in treatment-resistant epileptic children. Clin Drug Invest. 1996;11:214-223.
18. Pippenger CE. Pediatric clinical pharmacology of antiepileptic drugs: an especial consideration. In: Pippenger CE, Penry JK, Kutt H, eds. Antiepileptic Drugs: Quantitative Analysis and Interpretation. New York: Raven Press, 1978:315-319.
19. Rossi L, Nino L, Principi N. Correlation between age and plasma level/dosage ratio for phenobarbital in infants and children. Acta Pediatr Scand. 1979;68:431-434.
20. Battino D, Avanzini G, Bossi L, et al. Plasma levels of primidone and its metabolite phenobarbital: effects of age and associated therapy. Ther Drug Monit. 1983;5:73-79.
21. Cloyd J, Kriel R, Fischer J, et al. Pharmacokinetics of valproic acid in children I. Multiple antiepileptic drug therapy. Neurology. 1983;32:185-191.
22. Armijo JA, Herranz JL, Valiente R, et al. Concentration-dose relationship of antiepileptic drugs in pediatric outpatients during monotherapy: inter-individual variability and influence of age. Rev Farmacol Clin Exp. 1989;6:83-88.
23. Yukawa E, Suzuki A, Higuchi S, et al. Influence of age and concurrent medication on steady-state valproic acid serum level-dose ratios in Japanese paediatric patients. J Clin Pharmacol Ther. 1991;16:291-297.
24. Yukawa E, Suzuki A, Higuchi S, et al. Influence of age and co-medication on steady-state carbamazepine serum level-dose ratios in Japanese paediatric patients. J Clin Pharmacol Ther. 1992;17:65-69.
25. Yukawa E, Higuchi S, Aoyama T. Influence of age and co-medication on steady-state phenobarbital serum level-dose ratios in Japanese paediatric patients. J Clin Pharmacol Ther. 1992;17:249-253.
26. Armijo JA, Cuadrado A, Bravo J, et al. Vigabatrin serum concentration to dosage ratio: influence of age and associated antiepileptic drugs. Ther Drug Monit. 1997;19:491-498.
27. Armijo JA, Bravo J, Cuadrado A, et al. Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications. Ther Drug Monit. 1999;21:182-190.
28. Mahmood I, Tammara VK, Baweja RK. Does percent reduction in seizure frequency correlated with plasma concentration of anticonvulsant drugs? Experience with four anticonvulsants. Clin Pharmacol Ther. 1999;64:547-552.
29. Reife RA, Pledger G, Doose D, et al. Topiramate PK/PD analysis. Epilepsia. 1995;36(suppl 3):152.
30. Penovich PE, Schoroeder-Gustafson M, Gates JR, et al. Clinical experience with topiramate: correlation of serum levels with efficacy and adverse events. Epilepsia. 1997;38(suppl 8):181.
31. Twyman RE, Ben-Menachem E, Veloso F, et al. Plasma topiramate (TPM) concentration vs. therapeutic response during monotherapy. Epilepsia. 1999;40(suppl 7):111-112.
32. Schneiderman JH. Topiramate pharmacokinetics and pharmacodynamics. Can J Neurol Sci. 1998;25:3-5.
33. Garcia-Sáiz M, López-Gil A, Alfonso I, et al. Factors influencing cyclosporine blood concentration-to-dose ratio: a multivariate study. Ann Pharmacother. 2002;36:193-199.